Economic Evaluation of Axitinib for Second Line Treatment in Adult Patients with Advanced Renal Cell Carcinoma - the Portuguese Case.
نویسندگان
چکیده
Resource consumption was elicited by an expert panel, identifying inpatient and nursing home stays, visits, exams and analyses, for each disease state. Unit costs were based on Portuguese official sources: the Public Health Procurement Catalogue (SPMS) was used for drugs used at the hospital; hospitalizations and other hospital services were valued according to Portaria 20/2014 (Ministério da Saúde, 2014); and nursing home daily cost was taken from Portaria 360/2013 (Ministério da Saúde, 2013). ECONOMIC EVALUATION OF AXITINIB FOR SECOND LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA – THE PORTUGUESE CASE
منابع مشابه
Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report
BACKGROUND Renal cell carcinoma (RCC) with sarcomatoid differentiation is invasive, refractory to treatment, and has a higher mortality. Therefore, systemic therapy is still challenging, and the curative resection of localized or locally advanced RCC with sarcomatoid differentiation is very important. Axitinib is a potent and selective second-generation vascular endothelial growth factor recept...
متن کاملFeasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
BACKGROUND Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line therapy in Japanese patients with locally advanced RCC or mRCC. METHODS In this retrospective study...
متن کاملFirst-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.
BACKGROUND Sequential treatments using various targeted-therapies have been recommended for metastatic renal cell carcinoma. However, regimen selection remains difficult when adapting to various clinical situations. PATIENTS AND METHODS From 2006 to 2012, 29 patients who received sequential targeted-therapy at our hospital were included for analysis of the treatment regimens and outcome. RE...
متن کاملAn Unusual Case Report: Occurrence of Renal Cell Carcinoma, Basal Cell Carcinoma and Chronic Lymphocytic Leukemia in a Case of Papillary Thyroid Carcinoma Treated with Radioactive Iodine
The standard therapy for thyroid cancer is total or near total thyroidectomy, followed by the administration of radioactive iodine for remnant ablation or residual disease. Patients with radioiodine therapy are predisposed to second malignant neoplasms in organs such as central nervous system (CNS), breast, prostate, kidney, bone marrow, salivary gland, and digestive tract. Exposure to carcinog...
متن کاملComprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
The landscape of treatment for metastatic renal cell carcinoma (mRCC) continues to evolve. Although several new drugs have been approved for the treatment of this disease in recent years, mRCC remains incurable. Thus, the search continues for new effective therapies. One such novel compound is axitinib (Inlyta, Pfizer), a potent vascular endothelial growth factor receptor tyrosine kinase inhibi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014